Anika Therapeutics
ANIK
158 hedge funds and large institutions have $525M invested in Anika Therapeutics in 2020 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 61 reducing their positions, and 22 closing their positions.
164% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $4.78M
38% more capital invested
Capital invested by funds: $380M → $525M (+$145M)
5.4% more ownership
Funds ownership: 92.8% → 98.2% (+5.4%)
10% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 61
3% less funds holding
Funds holding: 163 → 158 (-5)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$9.68M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$8.87M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$6.41M |
| 4 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$3.73M |
| 5 |
Renaissance Technologies
New York
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.27M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.85M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
-$2.11M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.97M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.85M |
ANIK Hedge Fund Activity: Q2 2020 in Review
158 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2020, worth a combined $525M — up 38% from $380M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ANIK and 17 opened new positions — a net loss of 5 holders — while 61 trimmed existing stakes and 55 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $9.68M. The largest seller was Goldman Sachs, cutting an estimated $3.27M.
- 158 institutional investors held Anika Therapeutics (ANIK) as of Q2 2020, down from 163 in Q1 2020.
- Funds reported $525M of Anika Therapeutics stock for Q2 2020, up 38% quarter-over-quarter.
- 17 funds opened new Anika Therapeutics positions in Q2 2020 and 22 closed out, a net change of -5 holders.
- The largest Anika Therapeutics buyer in Q2 2020 was Acadian Asset Management, an estimated $9.68M added.
- The largest Anika Therapeutics seller in Q2 2020 was Goldman Sachs, an estimated $3.27M sold.
Based on aggregated 13F filings for Q2 2020.